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published online 13 June 2016
Caspases are a family of cysteine-rich proteases that activate
apoptotic pathways through their ‘initiator’ or ‘executioner’
pathways. Initiator caspases activate executioner caspase, such
as caspase-2, -3, -6 and -7, which hydrolyze or cleave structural
proteins in the cell leading to apoptosis. Caspase-2 is the most
highly conserved caspase and uniquely ﬁts into both initiator and
executioner categories and as such partakes in a variety of
apoptosis inducing signals including DNA damage, heat shock,
endoplasmic reticulum and oxidative stress. Caspase-2-deﬁcient
neurons are resistant to apoptosis induced by beta-amyloid
although it is involved in apoptosis of hippocampal neurons after
ischemia and is expressed in ischemic retinae.1
The protection of retinal ganglion cells (RGC), particularly after
trauma and numerous ocular pathologies such as glaucoma and
ischemic optic neuropathy, is of particular interest to the ocular
biology ﬁeld. RGC loss, a hallmark of these diseases leads to
vision loss and blindness.2 RGC are particularly susceptible and
in the rat optic nerve transection/crush model in adult rats, RGC
die rapidly and within 28 days, 90% of RGC are lost.3 As
apoptosis accounts for the majority of RGC death, treatments
that inhibit apoptosis afford limited neuroprotection, including
microglial inhibitors, brain-derived neurotrophic factor, over-
expression of Bcl-2 and caspase inhibitors.4 Caspase-3, -6, -8 and
-9 are all regarded as important for RGC apoptosis, however,
inhibition of these caspases, either alone or in speciﬁc
combinations afforded protection of up to 60% of RGC.5
Furthermore, our observations that cleaved caspase-3 was
absent in RGC and that little or no changes in cleaved
caspase-6 and -7 were detected after transection of RGC axons
by optic nerve crush (ONC) suggested that other caspases may
have a part in RGC apoptosis.3,6
We previously reported that RGCs exclusively expressed
activated (cleaved) caspase-2 after ONC in adult rats and
conﬁrmed these ﬁndings by employing an unbiased caspase
trapping assay.3,6 We further showed that inhibition of caspase-2
by either a pharmacological inhibitor6 or a chemically modiﬁed
synthetic short interfering RNA (siCASP2) signiﬁcantly protected
RGC from death, the latter protecting 495% of RGC from death
for up to 21 days after ONC.3,7 Here, we demonstrate in retinal
whole mounts, prepared after FluroGold backﬁlling of RGC,3,7 that
intravitreal injection of siCASP2 every 8 days protected RGC from
death at all radial quadrants from the optic disc including the
central, mid-periphery and outer quadrants, with 495% protec-
tion of RGC from death over the entire retina at 12 weeks after
ONC (Supplementary Figure S1), compared with intact controls
(2170 ± 200 in siCASP2 treated eyes versus 2250 ± 230 RGC/mm2
in intact controls). Only a small proportion of RGC were present
in retinal whole mounts from control scrambled siRNA-(siCNL3)
treated eyes (150± 130 RGC/mm2). Our results suggest that
neuroprotection by siCASP2 is extremely efﬁcient throughout
the entire retina and that this is an unprecedented level of
neuroprotection. To the best of our knowledge, our results far
exceed those of any others published in the literature. Our results
afﬁrm that caspase-2 is the main caspase responsible for the death
of RGC after direct trauma. This bodes well for siCASP2, otherwise
known as QPI-1007, currently recruiting patients in a worldwide
Phase III trial that is being initiated by Quark Pharmaceuticals Inc
(USA) (http://quarkpharma.com/?p = 12241).
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